Dose Augmentation of Tumor Necrosis Factor Inhibitors is Frequently Performed in Persons With Inflammatory Bowel Disease in the Absence of Objective Evidence of Active Inflammation
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Gastroenterology"
DOI: 10.1097/mcg.0000000000001391
Abstract: Background: Antitumor necrosis factor (anti-TNF) dose augmentation is frequently utilized in the management of inflammatory bowel disease (IBD), yet the extent to which clinicians assess for objective markers of inflammation before using the strategy is… read more here.
Keywords: anti tnf; objective evidence; augmentation; disease ... See more keywords